Intercept Pharmaceuticals Inc.

NASDAQ: ICPTHealthcare / Biotechnology / USA
79.69-1.70-2.09%Vol 381 3611Y Perf -6.53%
Jun 24th, 2019 16:00
BID79.64 ASK79.68
Open81.33 Previous Close81.39
Pre-Market- After-Trading79.69
 - -%  - -%
Target Price
154.47 
Analyst Rating
Strong Buy 1.50
Potencial %
93.84 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-100/-100/-100 
Growth Ranking
★+ —    -
Insiders Shares Cnt. % 3/6/12M
-100/-100/-100 
Income Ranking
 —    -
Market Cap (mil)2 374 
Earnings Rating
Strong Sell
Price Range Ratio 52wk %
11.00 
Earnings Date
1st Aug 2019

Today's Price Range

79.5782.01

52wk Range

73.01133.74

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Month
-9.27%
3 Months
-27.12%
6 Months
-7.84%
1 Year
-6.53%
3 Years
-44.24%
5 Years
-68.58%

Name / TickerPriceChg.Chg.%
ICPT79.69-1.7000-2.09
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
Q01 2019-2.57-3.03-17.90
Q04 2018-2.42-2.97-22.73
Q03 2018-2.65-2.1817.74
Q02 2018-2.83-2.588.83
Q01 2018-3.41-3.225.57
Q04 2017-3.57-4.43-24.09
Q03 2017-3.55-2.8918.59
Q02 2017-3.62-3.464.42
Earnings Per EndEstimateRevision %Trend
6/2019 QR-2.52-7.69Negative
9/2019 QR-2.26-6.10Negative
12/2019 FY-10.06-10.55Negative
12/2020 FY-8.78-42.07Negative
Next Report Date1st Aug 2019
Estimated EPS Next Report-2.52
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume381 361
Shares Outstanding (in ths.)29 786
Trades Count1 598
Dollar Volume22 959 662
Avg. Volume905 422
Avg. Weekly Volume436 818
Avg. Monthly Volume600 979
Avg. Quarterly Volume808 417
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (75.00 %)
12 (70.59 %)
11 (64.71 %)
Moderate Buy
2 (12.50 %)
2 (11.76 %)
2 (11.76 %)
Hold
1 (6.25 %)
1 (5.88 %)
2 (11.76 %)
Moderate Sell
0 (0.00 %)
1 (5.88 %)
1 (5.88 %)
Strong Sell
1 (6.25 %)
1 (5.88 %)
1 (5.88 %)
RatingStrong Buy
1.50
Moderate Buy
1.65
Moderate Buy
1.76

Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

CEO: Mark Pruzanski

Teplephone: +1 646 747-1000

Address: 10 Hudson Yards, New York 10011, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

40%60%

Bearish Bullish

70%30%

News